glp-1 dual agonist GIPR/GLP-1R therapies for diabetes and weight loss– Chemistry, Physiology and Clinical application Mechanisms of action of GLP-1

Tirzepatide is a dual GLP-1/GIP receptor agonist that has shown even greater weight loss in clinical trialsaveraging 22.5% of body weight over 72 weeks

A major strength of this research is its comprehensive subgroup analysis categorized by follow-up durations (3, 6, 12, and 24 months)

Patients should plan for the program to end on December 31, 2027 unless extended

Symptoms include shakiness, sweating, confusion, rapid heartbeat, and in severe cases, loss of consciousness

This review delves into the present comprehension of GLP-1R signaling in immune cells and emphasizes the therapeutic potential of GLP-1RAs in treating autoimmune and autoinflammatory diseases

Panchaprateep R, Asawanonda P